Overview

APO-VORICONAZOLE 50 MG contains VORICONAZOLE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02409674, held by APOTEX INC, supplied as TABLET for ORAL administration. Nexara Health is a licensed Canadian wholesale distributor and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

Product details

Indications

Invasive aspergillosis; Candidemia in non-neutropenic patients and specific Candida infections (disseminated skin, abdomen, kidney, bladder wall, and wounds).

Dosage and administration

Loading dose: 400 mg BID (Day 1); Maintenance: 200 mg BID. Adjust based on weight (<40 kg) and response. Take 1 hour before or 2 hours after meals. Halve maintenance dose in mild-moderate hepatic impairment.

Contraindications

Hypersensitivity to voriconazole; coadministration with CYP3A4 substrates (e.g., quinidine, sirolimus, pimozide, lurasidone, ivabradine, naloxegol, tolvaptan, venetoclax) or inducers (e.g., rifampin).

Warnings and precautions

Serious drug interactions; QT interval prolongation; visual disturbances; hepatic toxicity; severe cutaneous adverse reactions (SCARs); teratogenicity; and musculoskeletal (fluorosis/periostitis).

Storage and handling

Not explicitly detailed in provided text (standard section 11 was listed in TOC but text cut off), though typically 15-30°C for tablets.

Packaging

HDPE bottles of 30 tablets.

Alternatives in the same therapeutic class

Products sharing ATC code J02AC03 VORICONAZOLE. Marketed products are listed first. Substitution decisions rest with the prescriber or pharmacist, and interchangeability is determined provincially.